Alkermes Acquires Avadel, Expands Sleep Health Business – Merger Arbitrage Mondays

Avadel Pharmaceuticals plc (AVDL): $18.56

Market Cap: $1.79B

Deal Size: $2.1B

This week, we are writing about not one, but two new deals with CVRs that we find interesting, including one that we added to our portfolio earlier this year when it was trading at less than half of its acquisition price.

Alkermes plc (ALKS) entered a merger agreement on October 22, 2025, to acquire Avadel Pharmaceuticals in a deal valued at $2.1 billion, gaining an FDA-approved sleep-disorder treatment and expanding into the sleep medicine market.

Only plus or premium subscribers can access this post. Subscribe today.